Tumor immune contexture is a determinant of anti-cd19 car t cell efficacy in large b cell lymphoma

HIGHLIGHTS

• who: Nathalie Scholler from the USA The University have published the research: Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma, in the Journal: (JOURNAL) of 12/02/2021
• what: This study demonstrated that TME gene signature evolution occurs quickly after axi-cel treatment whereby responders show rapid upregulation of the T cell-related signature and downregulation of B cell tumor-related markers defining dynamic pattern that separates responders from non-responders within 2 weeks post-treatment.
• future: Axi-cel expansion relative to TB . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.